
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) is viewed positively by numerous analysts, with many highlighting its robust growth potential, especially in the Asian market and wealth management. The company has successfully increased its dividend yield, currently sitting at approximately 4-5%, while its price-to-earnings (PE) ratio remains attractive compared to peers in the banking sector. Analysts have noted concerns over potential earnings drops but maintain a long-term positive outlook, suggesting that MFC is suitable for income-focused investors. While many emphasize the reliability of MFC's dividend and its strong position in life insurance, there are mixed feelings regarding its growth prospects compared to other financial institutions. Overall, the sentiment leans towards MFC being a solid choice for those seeking steady income and moderate growth, but some experts advise caution regarding market volatility.
He is warm to the life insurance business, but does not own this. They over leveraged themselves during the financial crisis. They have some legacy US assets that have hurt their numbers. To unleveraged themselves to interests, it has hurt as interest rates have begun to rise. He questions their management decisions. If you own it, hold it, but there are better ones.
This is the insurance company they own in their portfolios. The company has pulled back below $25. You can start building a position here. She likes their 30% exposure in Asia, which provides higher growth. It has legacy problems in the US, such as John Hancock. They can’t just sell these, and they weigh on valuation. It will take a while to work through these issues, but she likes their asset management, their wealth management business and their core insurance business.
Heowns Sunlife instead. Of all the large Canadian financials, Manulife has the strongest earnings growth projections at 15% largely from more fees in asset management side and from their Asian enterprise. Sunlife has greater consistency in earnings growth and higher yield. Manulife's U.S. operations will benefit from U.S. tax cuts.
With a rising interest rate environment, this company is well positioned and is his favourite insurance company within the alternatives. 50% of core earnings are now coming from Asia and also their global wealth and asset management businesses. That’s a very high margin and high growth. Under the new president, they are going under a very concentrated resource optimization. A concern over the last few years has been their exposure to long-term care, variable annuities, etc. in the US. That is going to be significantly addressed. He wouldn't be surprised to see dividend increases. Dividend yield of 3%. (Analysts' price target is $31.)
Lifecos are widely believed to be the biggest beneficiaries of higher interest rates, due to large amount of long-term assets they hold, and that they discount their policies. There have been some strong recommendations by brokers on these companies this year. This one has struggled with its debacle in 2008 and then we saw the fortress balance sheet being built. When they do that, they are not taking aggressive action to grow. This has now recovered and is now focusing on their stronger assets, which is Asia. However, there are $2 billion of tax losses they have to forgo because of the change in tax legislation in the US. $30 - $32 would be his target for 12 months.
Except for the nasty bump in 2008, this was like a "buy and forget it" type of company. Always had a dividend increase every year. Record earnings. The last few years have been ugly in terms of taking write-downs, they are still making a lot of money. He likes their Asian exposure. He wouldn't sell.
Rising interest rates should be a bit of a tailwind for them. The demographics for people looking to annuitize their wealth in wealth management, are good for this company. He feels the new CEO is on track to continue turning the company around. Has a good understanding of the Asian/Pacific business. Dividend yield of 3.1%. (Analysts' price target is $30.)
MFC-T vs. SLF-T. They are both in the right area. They do well seasonally at this time. He would favour SLF-T from a technical perspective. It has a rising bottom. It has pulled back down a little today. He favours banks over lifecos.